Literature DB >> 25212768

Reference datasets for 2-treatment, 2-sequence, 2-period bioequivalence studies.

Helmut Schütz1, Detlew Labes, Anders Fuglsang.   

Abstract

It is difficult to validate statistical software used to assess bioequivalence since very few datasets with known results are in the public domain, and the few that are published are of moderate size and balanced. The purpose of this paper is therefore to introduce reference datasets of varying complexity in terms of dataset size and characteristics (balance, range, outlier presence, residual error distribution) for 2-treatment, 2-period, 2-sequence bioequivalence studies and to report their point estimates and 90% confidence intervals which companies can use to validate their installations. The results for these datasets were calculated using the commercial packages EquivTest, Kinetica, SAS and WinNonlin, and the non-commercial package R. The results of three of these packages mostly agree, but imbalance between sequences seems to provoke questionable results with one package, which illustrates well the need for proper software validation.

Mesh:

Year:  2014        PMID: 25212768      PMCID: PMC4389751          DOI: 10.1208/s12248-014-9661-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  2 in total

1.  Presentation of results from bioequivalence studies.

Authors:  R Sauter; V W Steinijans; E Diletti; A Böhm; H U Schulz
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992

2.  The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before and after food.

Authors:  D Clayton; A Leslie
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

  2 in total
  3 in total

1.  Reference datasets for bioequivalence trials in a two-group parallel design.

Authors:  Anders Fuglsang; Helmut Schütz; Detlew Labes
Journal:  AAPS J       Date:  2014-12-09       Impact factor: 4.009

2.  On the Incorrect Statistical Calculations of the Kinetica Software Package in Imbalanced Designs.

Authors:  S Morales-Alcelay; J M de la Torre de Alvarado; A García-Arieta
Journal:  AAPS J       Date:  2015-03-19       Impact factor: 4.009

3.  Reference Datasets for Studies in a Replicate Design Intended for Average Bioequivalence with Expanding Limits.

Authors:  Helmut Schütz; Detlew Labes; Michael Tomashevskiy; Mario González-de la Parra; Anastasia Shitova; Anders Fuglsang
Journal:  AAPS J       Date:  2020-02-07       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.